| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-64775-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-179SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65805SS | |||
| Azide and BSA Free | NBP2-80660 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-101SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76701SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-74396SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22115SS | |||
| Azide and BSA Free | NBP2-80618 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-49045SS | |||
| Azide and BSA Free | NBP2-80658 | |||
![Immunohistochemistry-Frozen: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis of Mouse colon cancer tissue using HLA ABC antibody (W6/32). Primary antibody dilution was 1:100. Sample was incubated with secondary antibody in 1:300 dilution. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Immunohistochemistry-Frozen-NB100-64775-img0015.jpg "Immunohistochemistry-Frozen: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis of Mouse colon cancer tissue using HLA ABC antibody (W6/32). Primary antibody dilution was 1:100. Sample was incubated with secondary antibody in 1:300 dilution. Image from verified customer review.")
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis using the FITC conjugate of NB100-64775. Staining of normal human peripheral blood cells with Mouse IgG2a K Isotype Control FITC (NBP1-43955) (blue histogram) or Anti-Human HLA-ABC FITC (purple histogram). Cells in the lymphocyte gate were used f](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0013.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0002.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:Alexa Fluor 488.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0004.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:Alexa Fluor 647.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0006.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:FITC.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0007.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood monocytes with Mouse anti Human HLA ABC:Biotin.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0008.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Human lymphoblast. Image provided via verified customer review.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0009.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of peripheral blood lymphocytes with anti-HLA-ABC: Low Endotoxin.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0010.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis using the PE/Cy5 conjugate of NB100-64775. Staining of normal human peripheral blood cells with Mouse IgG2a K Isotype Control PE-Cy5 (NBP1-43073) (blue histogram) or Anti-Human HLA-ABC PE-Cy5 (purple histogram). Cells in the lymphocyte gate were](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0014.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse fore brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0020.jpg "Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse fore brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min")
![Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 Antibody (1 1:1000, Red) expression in dorsal root ganglia. Green fluorescent Nissl was used as counter-staining. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-19019-img0002.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse cerebellum stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0007.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat brain stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0010.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat cerebellum stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0011.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat hind brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0016.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Analysis of paraffin-embedded human hepatoma, using at 1:500 dilution.Iba1 antibody detects AIF-1/Iba1 in the cytosol of Kupffer cell in human hepatoma by immunohistochemical analysis.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0018.jpg)
![Immunohistochemistry: AIF-1/Iba1 Antibody [NBP2-19019] - LCN2 mainly expressed on neurons. a Representative immunofluorescence images of LCN2 (green) and AIF-1/Iba1 (red) staining in sections of the hippocampus after surgery. Long scale bar, 600 um; short scale bar, 25 um. Image collected and cropped by CiteAb from the following publication (pubmed.ncbi.nlm.nih.gov/35413913) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-2552023153956.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - LCN2 mainly expressed on neurons. a Representative immunofluorescence images of LCN2 (green), GFAP (red), NeuN (red) & IbaI (red) staining in sections of the hippocampus after surgery. Long scale bar, 600 µm; short scale bar, 25 µm. b Percentage quantification of LCN2 positive cells (n = 3 mice/group). c Cartoon depicting MACS sorting procedures for isolating CD11b+ & CD11b − cells. d Relative expression of cx3cr1 in CD11b + & CD11b − cells after sorting from all samples. d Relative expression level of Lcn2 mRNA in CD11b + & CD11b − cells from hippocampus 6 h after surgery. e Relative expression level of IL-6 mRNA in CD11b + cells. Data are represented as mean ± SEM. **** P Sample: Frozen-sectioned mouse brain.Green: AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Blue: Fluoroshield with DAPI .Antigen Retrieval: ice-cold MeOH for 5 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242091448.jpg)
![Western Blot: AIF-1/Iba1 Antibody [NBP2-19019] - Rat tissue extract (50 ug) was separated by 15% SDS-PAGE, and the membrane was blotted with AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242075976.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein by immunohistochemical analysis.Sample: Paraffin-embedded rat tissues.AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:100.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-910202420115036.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein at cell membrane by immunofluorescent analysis.Sample: THP-1 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242011504.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis.Sample: Paraffin-embedded mouse brain.AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-910202419593534.jpg)
![Iba1 antibody detects Iba1 protein expression at microglias by immunohistochemical analysis.Sample: Frozen sectioned E13.5 Rat brain. Green: Iba1 protein stained by Iba1 antibody (NBP2-19019) diluted at 1:250.Red: beta Tubulin 3/ TUJ1, a mature neuron marker, stained by beta Tubulin 3/ TUJ1 antibody [GT11710] diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-immunohistochemistry-frozen-2611202518272320.jpg)
![Western Blot: NOX1 Antibody [NBP1-31546] - Representative Western blots showing Nox1 and beta-tubulin in PC-3 cells or Nox4 and beta-tubulin in C2C12 cells, at 5% and 18% O2. Total cellular proteins were extracted by treating cells with NP-40 buffer (150mM NaCl, 1% NP-40, 50mM Tris-HCl pH8.0). Total protein (15ug per sample) was resolved on 10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane, and probed for Nox1 or Nox4. beta-Tubulin was used as an internal loading and transfer control. All antibodies were purchased from Novus Biologicals; Nox1 (NBP1-31546), Nox4 (NB110-58851), b-tubulin (NB600-936). Data were analysed using two-tailed Student's t-tests. Bars represent means+/-SEM from at least five independent experiments. pSample: Paraffin-embedded human lung carcinoma.NOX1 antibody diluted at 1:500.Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/NOX1-Antibody-Immunohistochemistry-Paraffin-NBP1-31546-img0005.jpg "Western Blot: NOX1 Antibody [NBP1-31546] - Representative Western blots showing Nox1 and beta-tubulin in PC-3 cells or Nox4 and beta-tubulin in C2C12 cells, at 5% and 18% O2. Total cellular proteins were extracted by treating cells with NP-40 buffer (150mM NaCl, 1% NP-40, 50mM Tris-HCl pH8.0). Total protein (15ug per sample) was resolved on 10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane, and probed for Nox1 or Nox4. beta-Tubulin was used as an internal loading and transfer control. All antibodies were purchased from Novus Biologicals; Nox1 (NBP1-31546), Nox4 (NB110-58851), b-tubulin (NB600-936). Data were analysed using two-tailed Student's t-tests. Bars represent means+/-SEM from at least five independent experiments. pSample: Paraffin-embedded human lung carcinoma.NOX1 antibody diluted at 1:500.Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min")
![Western Blot: NOX1 Antibody [NBP1-31546] - Blueberry polyphenol extract (BPE) did not affect the expression of NADPH oxidases (NOX) in angiotensin (Ang) II-treated human aortic endothelial cells (HAECs). HAECs were treated with 200 µg/mL of BPE for 1 h then treated with 200 nM of Ang II for 12 h. Protein expression of NOX1 (A,B), NOX2 (C,D), NOX4 (E,F), & NOX5 (G,H) were determined by Western blot. Quantification was performed using Image Lab (Bio-Rad Laboratories, Inc.). Data are expressed as mean ± SD from three (NOX1 & NOX4) & five (NOX2 & NOX5) independent experiments. Values that do not share the same letter are significantly different from each other (p ≤ 0.05). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35453301), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31546_rabbit-polyclonal-nox1-antibody-31020241517138.jpg)
![Simple Western: 15-PGDH/HPGD Antibody [NB200-179] - Simple Western lane view shows a specific band for 15-PGDH/HPGD in 0.5 mg/ml of Lovo (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Simple-Western-NB200-179-img0005.jpg "Simple Western: 15-PGDH/HPGD Antibody [NB200-179] - Simple Western lane view shows a specific band for 15-PGDH/HPGD in 0.5 mg/ml of Lovo (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy and inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) and patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: x250 (a, b), x100 (c, d). Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar3851), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0015.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH/HPGD) in rheumatoid arthritis synovial tissue and the effects of anti-rheumatic treatment on its expression. Double-immunofluorescence images show staining for 15-PGDH/HPGD-positive (red) cells and cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, and endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: x400. Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar3851), licensed under a CC-BY license](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0016.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Western blot analysis of 15-PGDH in Lovo cell lysate.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Western-Blot-NB200-179-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - Confocal microscopy immunofluorescence images showing the expression of 15-PGDH (in green; antibody dilution, 1:200; DAPI in blue) after 24 h of stimulation with LTC4 in Caco-2 cells. The objective used was 63x. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunocytochemistry-Immunofluorescence-NB200-179-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - 15-PGDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunocytochemistry-Immunofluorescence-NB200-179-img0004.jpg)
![Immunohistochemistry-Paraffin: 15-PGDH/HPGD Antibody [NB200-179] - IHC analysis of 15-PGDH in human synovial tissue from patient with rheumatoid arthritis . Image courtesy of an anonymous customer review.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-Paraffin-NB200-179-img0003.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Staining in human fetal membrane tissue. Image from verified customer review.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - A representative western blot and densitometric analysis of LTC4-induced SI protein expression after transfection with a scrambled control siRNA or 15-PGDH siRNA in HT-29 cells are shown. The cells were treated with or without 40 nM LTC4 for 48 h, and the change in the SI protein level was detected using an SI-specific antibody (1:1000 dilution) and 15-PGDH was detected using a 15-PGDH antibody (1:5000 dilution). The membrane was re-probed with an antibody against beta-actin to ensure equal loading. Statistical analysis was conducted using an unpaired t-test; *P=0.05, **P<0.01. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD Antibody-Knockdown Validated-NB200-179-img0018.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415291984.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415384117.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-31020241539722.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415291976.jpg)
![Immunocytochemistry/ Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue & the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells & cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, & endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before & after intra-articular treatment with glucocorticoids (b) & before & 8 weeks after initiation of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before & after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-31020241621232.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Effect of LTC4 on 15-PGDH expression in the colon cancer cell line Caco-2(A) Quantification by qPCR of the mRNA expression of 15-PGDH following treatment with 40 nM LTC4 for 48 h in the presence or absence of AP100984 (a CysLT2 receptor antagonist, 1 μM) & JNK inhibitor I (10 μM). (B) Western blot showing 15-PGDH expression (antibody dilution, 1:5000) & densitometric analysis of LTC4-induced 15-PGDH up-regulation before or after the cells were stimulated with 40 nM LTC4 in the presence or absence of AP100984 & JNK inhibitor I for 48 h. (C) Confocal microscopy immunofluorescence images showing the expression of 15-PGDH (in green; antibody dilution, 1:200; DAPI in blue) after 24 h of stimulation with LTC4 in Caco-2 cells. The objective used was 63x. The data are presented as the percent of untreated control cells & represent the mean ± SEM of at least three separate experiments. Statistical analysis was conducted using an unpaired t-test; *P≤0.05, **P<0.01, ***P<0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416205174.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Effect of 15-PGDH down-regulation on the cell differentiation markers SI & Mucin-2(A) A representative western blot & densitometric analysis of LTC4-induced SI protein expression after transfection with a scrambled control siRNA or 15-PGDH siRNA in HT-29 cells are shown. The cells were treated with or without 40 nM LTC4 for 48 h, & the change in the SI protein level was detected using an SI-specific antibody (1:1000 dilution) & 15-PGDH was detected using a 15-PGDH antibody (1:5000 dilution). The membrane was re-probed with an antibody against beta –actin to ensure equal loading. (B) A representative western blot & densitometric analysis performed as in (A) shown here for Caco-2 cells. (C, D) Representative confocal microscopy immunofluorescence images from cells transfected with a scrambled control siRNA or 15-PGDH siRNA with or without stimulation with 40 nM LTC4 for 48 h. The expression of Mucin-2 (in red; antibody dilution, 1:500; DAPI in blue, dilution 1:1000) (C) in HT-29 cells & (D) Caco-2 cells is shown. The objective used was 63x, & the scale bar is 50 μm. The data are presented as the percent of control cells & represent the mean ± SEM of at least three separate experiments. Statistical analysis was conducted using an unpaired t-test; *P≤0.05, **P<0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416212329.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue & the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells & cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, & endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before & after intra-articular treatment with glucocorticoids (b) & before & 8 weeks after initiation of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before & after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416205129.jpg)
![Western Blot: CD81 Antibody (1D6) [NB100-65805] - Isolation and characterization of exosomes from cell culture supernatant and human blood. Immunoblot of exosomal markers CD81 (~30 kDa), CD63 (~55 kDa), and LAMP2B (~50 kDa) in exosomes (5 ug lysates) isolated from the serum of breast cancer patients and healthy control. Grp94 (~100 kDa) and beta-actin (~42 kDa) serve as a negative control and a loading control, respectively. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep36502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Western-Blot-NB100-65805-img0015.jpg "Western Blot: CD81 Antibody (1D6) [NB100-65805] - Isolation and characterization of exosomes from cell culture supernatant and human blood. Immunoblot of exosomal markers CD81 (~30 kDa), CD63 (~55 kDa), and LAMP2B (~50 kDa) in exosomes (5 ug lysates) isolated from the serum of breast cancer patients and healthy control. Grp94 (~100 kDa) and beta-actin (~42 kDa) serve as a negative control and a loading control, respectively. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep36502), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CD81 Antibody (1D6) [NB100-65805] - Staining of TAPA1 in human testis using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Immunohistochemistry-Paraffin-NB100-65805-img0003.jpg)
![Flow Cytometry: CD81 Antibody (1D6) - BSA Free [NB100-65805] - A surface stain was performed on Jurkat cells with CD81 Antibody (1D6) NB100-65805 (blue) and a matched isotype control MAB002 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-BSA-Free-Flow-Cytometry-NB100-65805-img0016.jpg)
![Western Blot: CD81 Antibody (1D6) [NB100-65805] - Analysis of human testis tissue (A) using CD81 antibody at a concentration of 2 ug/mL.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Western-Blot-NB100-65805-img0007.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - Surface flow cytometric staining of 1 x 10^6 PBMC cells using CD81 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1 x 10^6 cells was used.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0009.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - Staining of human peripheral blood lymphocytes.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0001.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - Analysis using the FITC conjugate of NB100-65805. Staining of human peripheral blood lymphocytes.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0011.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - A surface stain was performed on Jurkat cells with CD81 (1D6) antibody NB100-65805AF647(blue) and a matched isotype control NBP2-27287AF647 (orange). Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0012.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - A surface stain was performed on Jurkat Cells with CD81 Antibody (1D6) NB100-65805B and a matched isotype control. Both antibodies were conjugated to biotin. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0013.jpg)
![Flow Cytometry: CD81 Antibody (1D6) [NB100-65805] - A surface stain was performed on Jurkat cells with CD81 Antibody [1D6] NB100-65805AF488 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD81-Antibody-1D6-Flow-Cytometry-NB100-65805-img0014.jpg)
![Western Blot: CD81 Antibody (1D6) - BSA Free [NB100-65805] - Characterization & internalization of M2-Exos. (A) TEM image of M2-Exos. Scale bar: 200 nm. (B) DLS measurement of M2-Exos size. (C) Western blotting assay of exosomal markers in THP-1-M2 cellular lysate & M2-Exos preparation. (D,F) Fluorescence images of 786-O & ACHN cells treated with or without PKH67-labeled M2-Exos (green). Scale bar: 50 μm. (E,G) Three-dimensional confocal reconstruction of 786-O & ACHN cells treated with PKH67-labeled M2-Exos (green). (H) Fluorescence staining analyzing the internalization of M2-Exos by 786-O cells over 12 h. Scale bar: 10 μm. CT: control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35328425), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-65805_mouse-monoclonal-cd81-antibody-1d6-310202415382443.jpg)
![Western Blot: Calreticulin Antibody [NB600-101] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and Calreticulin knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1500 of Rabbit Anti-Human Calreticulin Polyclonal Antibody (Catalog # NB600-101) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for Calreticulin at approximately 55 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Knockdown-Validated-NB600-101-img0011.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Calreticulin Antibody [NB600-101] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and Calreticulin knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1500 of Rabbit Anti-Human Calreticulin Polyclonal Antibody (Catalog # NB600-101) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for Calreticulin at approximately 55 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: Calreticulin Antibody [NB600-101] - Human kidney lysate.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Western-Blot-NB600-101-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody [NB600-101] - Immunofluorescence staining of Calreticulin in HCT15 colon cancer cells using NB600-101. Secondary antibody was conjugated with Alexa Fluor 488. Photo courtesy of Dr. Birkenkamp Demtroeder, Arhus University Hospital.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunocytochemistry-Immunofluorescence-NB600-101-img0005.jpg)
![Immunohistochemistry-Paraffin: Calreticulin Antibody [NB600-101] - Analysis of a FFPE tissue section of human thyroid gland using 1:50 dilution of Calreticulin antibody. The signal was developed using HRP-DAB based detection method which followed counterstaining of the nuclei with hematoxylin. This representative section shows a strong positivity of Calreticulin in the follicular epithelial cells, wherein the signal was found to be very intense in the perinuclear region of the cells which correlates well with Endoplasmic reticulum localization of this protein. The para-follicular cells, endothelial cells of blood vessels (not the RBCs though) and the loose connective tissue in the section showed a weak cytoplasmic staining. Some staining was observed in the follicles/colloids also which is potentially the secreted form of Calreticulin.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunohistochemistry-Paraffin-NB600-101-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody [NB600-101] - The Calreticulin antibody NB600-101 was tested in HeLa cells at a 1:250 dilution against DyLight 488 (Green). Alpha-tubulin and nuclei were counterstained against DyLight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunocytochemistry-Immunofluorescence-NB600-101-img0007.jpg)
![Immunohistochemistry-Paraffin: Calreticulin Antibody [NB600-101] - Analysis of a FFPE tissue section of human thyroid gland using 1:50 dilution of Calreticulin antibody. The signal was developed using HRP-DAB based detection method which followed counterstaining of the nuclei with hematoxylin. This representative section shows a strong positivity of Calreticulin in the follicular epithelial cells, wherein the signal was found to be very intense in the perinuclear region of the cells which correlates well with Endoplasmic reticulum localization of this protein. The para-follicular cells, endothelial cells and the loose connective tissue in the section showed a weak cytoplasmic staining. Some staining was observed in the follicles/colloids also which is potentially the secreted form of Calreticulin.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunohistochemistry-Paraffin-NB600-101-img0009.jpg)
![Simple Western: Calreticulin Antibody [NB600-101] - Lane view shows a specific band for Calreticulin in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Simple-Western-NB600-101-img0008.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0016.jpg "<b>Biological Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Analysis of human uterus tissue using anti-TIM-1 antibody (3809) at 10 ug/ml.Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 C. A goat anti-rabbit IgG H&L (HRP)at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunohistochemistry-Paraffin-NBP1-76701-img0013.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of NIH/3T3 cell lysates. Antibodies: TIM-1 3809 (8 ug/mL), overnight incubation at 4 C in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0010.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of lysates per lane. Antibodies: TIM-1 3809 (8 ug/mL), TIM-13811 (1 ug/mL), beta-actin (1 ug/mL), and GAPDH (0.02 ug/mL), overnightincubation at 4C (3809) or 1h incubation at RT in 5% NFDM/TBST. Secondary:Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0012.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - HeLa cells were transfected with control siRNAs (lane 1) or TIM-1 siRNAs (lane 2) Loading: 15 ug of HeLa whole cell lysates per lane. Antibodies: 3809 (8 ug/mL), 1 hincubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0015.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 u of lysates per lane.Antibodies: TIM-1 (8 u/mL), overnight incubation at 4; C in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-2711202420171718.gif)
![Immunocytochemistry/ Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Validation of TIM-1/KIM-1/HAVCR in Human Uterus Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human uterus cells labeling TIM-1/KIM-1/HAVCR with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on human uterus cells.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-271120241937768.jpg)
![Immunocytochemistry/Immunofluorescence: CXCR4 Antibody [NB100-74396] - Optimization of immunofluorescence staining of CXCR4 protein. MDA, PC3, KG1 cells were used for the optimization experiments. Cells were seeded onto cell-tak coated 48 mm coverslips in a 48-well plate. Cells were fixed with 2% formaldehyde for 20 min, washed with PBS. After fixation, cells were blocked with 2.0% BSA in PBS for 1 h at room temperature. All the cells were incubated with a primary antibody for anti-rabbit CXCR4 for 1 h. After washing with PBS, cells were put in respective secondary antibodies-anti-rabbit dylight 405 for 1 h. PSMA= Magenta, EpCAM= Yellow, sLex= Green, CXCR4= Red, and Merge shows all the colors. MDA=PSMA+, EpCAM+, sLex+, CXCR4+. PC3 = PSMA-, EpCAM+, sLex-, CXCR4+. KG1 = PSMA-, EpCAM-, sLex+, CXCR4-. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0085143) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74396-img0008.jpg "Immunocytochemistry/Immunofluorescence: CXCR4 Antibody [NB100-74396] - Optimization of immunofluorescence staining of CXCR4 protein. MDA, PC3, KG1 cells were used for the optimization experiments. Cells were seeded onto cell-tak coated 48 mm coverslips in a 48-well plate. Cells were fixed with 2% formaldehyde for 20 min, washed with PBS. After fixation, cells were blocked with 2.0% BSA in PBS for 1 h at room temperature. All the cells were incubated with a primary antibody for anti-rabbit CXCR4 for 1 h. After washing with PBS, cells were put in respective secondary antibodies-anti-rabbit dylight 405 for 1 h. PSMA= Magenta, EpCAM= Yellow, sLex= Green, CXCR4= Red, and Merge shows all the colors. MDA=PSMA+, EpCAM+, sLex+, CXCR4+. PC3 = PSMA-, EpCAM+, sLex-, CXCR4+. KG1 = PSMA-, EpCAM-, sLex+, CXCR4-. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0085143) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: CXCR4 Antibody [NB100-74396] - The A2AR and baicalin attenuated CXCR4 expression in the hypoxia-induced PAH mouse model. CXCR4 protein expression levels in lung tissue were examined by western blot. GAPDH served as an internal control (c, d; n = 3). Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC5543745/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Western-Blot-NB100-74396-img0012.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CXCR4 Antibody [NB100-74396] - Pep R54 in combination with nivolumab reduced the expression of CXCR4-CXCL12 and PD-L1 in PES43 tumors. Representative IHC pictures (magnification 400x) for CXCR4, CXCR7 (red staining), CXCL12, PD-1 and PD-L1 expression (brown staining) in PES43 collected tumors from mice treated with Pep R54, nivolumab or combined treatment. Image collected and cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/s13046-019-1420-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunohistochemistry-NB100-74396-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CXCR4 Antibody [NB100-74396] - Pep R in combination with anti-PD-1 reduced the expression of CXCR4-CXCL12 and PD-L1 in MC38 tumors. Representative IHC pictures for CXCR4, CXCR7, CXCL12, PD-1 and PD-L1 expression (brown staining) in MC38 collected tumors (magnification 400x), from mice treated with Pep R, anti-murine PD-1 or combined treatment showing the reduction of CXCR4, CXCL12 and PD-L1 expression in mice treated with Pep R alone and in combination with anti-PD-1Image collected and cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/s13046-019-1420-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunohistochemistry-NB100-74396-img0011.jpg)
![Western Blot: CXCR4 Antibody [NB100-74396] - Analysis of CXCR4 in HeLa whole cell extract.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Western-Blot-NB100-74396-img0002.jpg)
![Western Blot: CXCR4 Antibody [NB100-74396] - Analysis of CXCR4 protein in human small intestine tissue lysate using 1:500 dilution of rabbit polyclonal CXCR4 antibody (Lot A2). The signal was developed using ECL method and the antibody generated a specific band of CXCR4 at ~40 kDa position.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Western-Blot-NB100-74396-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: CXCR4 Antibody [NB100-74396] - CXCR4 antibody was tested in HeLa cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74396-img0003.jpg)
![Immunohistochemistry: CXCR4 Antibody [NB100-74396] - Immunostaining of CXCR4 in human cervical carcinoma tissue sections.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunohistochemistry-NB100-74396-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: CXCR4 Antibody [NB100-74396] - The A2AR & baicalin attenuated CXCR4 expression in the hypoxia-induced PAH mouse model. CXCR4 & MYH11 expression levels in mouse PASMCs were analyzed by immunofluorescence staining (a; n = 3). CXCR4 protein is stained red, & MYH11 is stained green to indicate the PASMCs (×400; scale bars indicate 50 μm). CXCR4 fluorescence intensity was calculated (b; n = 3). CXCR4 protein expression levels in lung tissue were examined by western blot. GAPDH served as an internal control (c, d; n = 3). Data are presented as the mean ± SD. #Value significantly greater than the corresponding value in saline-treated normoxic mice (##P 50 CTCs/ 2.5 ml blood) was processed via ficoll density centrifugation & the PBMC fraction was collected. Immunomagnetic anti-CD45 depletion was performed on the obtained PBMCs & the remaining cells were washed, cytospunned onto the slides. Slides were stained for PSMA, EpCAM, sLex, & CXCR4 using the protocol as described in Figure S1. MDA, PC3, & KG1 cells were simultaneously stained as a control for the following markers: PSMA= Magenta, EpCAM= Yellow, HECA-452= Green, CXCR4= Red. All prostate CTCs expressed CXCR4, while, sLex expression was variable. The analysis of sLex intensity is shown in Figure 4. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24386459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74396_rabbit-polyclonal-cxcr4-antibody-31020241682122.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0003.jpg "Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.")
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of HepG2 cells using A) MCP1 mAb (green), DRAQ5 fluorescent DNA dye (blue), and Actin filaments have been labeled with Alexa Fluor-555 phalloidin (red). B) Staining without MCP1 mAb](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0011.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - HER2 activates NF-kB and upregulates CCL2. MGs from FVB wild-type and 22-week-old MMTV-HER2 mice stained against CCL2, HER2, and CCR2. Bars: 25 um. Inset, CCR2 signal, zoom factor 1x; full image in Supplementary Fig. 5i. CCL2 intensity was quantified using ROI tool in Metamorph (Supplementary Fig. 5h). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0009.jpg)
![Flow Cytometry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of A549 cells using MCP1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Flow-Cytometry-NBP2-22115-img0004.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mAb against human MCP1 (AA: 1-99) recombinant protein. (Expected MW is 36.5 kDa)](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - CCL2 staining in acini cultures from MMTV-HER2 MGs (20-24 weeks) grown for 5 days and then DMSO-treated (vehicle control, e), 1uM lapatinib (f) or 1 uM IKKi compound A (g) for 24 hrs. Bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Organotypic specimens were treated with anti-LIF for 72 h and then cultured with PBMCs for 24 h. CXCL9 and CCL2 mRNA expression levels are shown. Representative images (patient 4, 5, 6) of CFSE-stained PBMCs into Matrigel containing GBM specimens and IF of the indicated factors in organotypic tissues are displayed. Bars represent quantification of five different fields of each condition. Data are presented as mean +/- SD. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0012.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of paraffin-embedded liver cancer tissues using MCP1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-Paraffin-NBP2-22115-img0007.jpg)
![ELISA: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Red: Control Antigen (100ng), Purple: Antigen (10ng), Green: Antigen (50ng), Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-ELISA-NBP2-22115-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202415384136.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF represses CXCL9 through epigenetic silencing. a, b qRT-PCR analysis of the indicated genes in BMDMs. BMDMs were pre-incubated with 20 ng/ml LIF for 72 h & then stimulated with 5 ng/ml IFN gamma or 10 μg/ml IL4 during 6 h (a) or with 0.1, 0.5, 1 & 5 ng/ml IFN gamma for 24 h (b). c CXCL9 ELISA from BMDMs pre-incubated with 20 ng/ml LIF & then stimulated with 0.1 ng/ml IFN gamma for 24 h. d CXCL9 ELISA from human CD11b+sorted cells (77% CD11b+ CD14+, see Supplementary Fig. 7b, c) from human GBM cultured with 20 ng/ml LIF for 72 h & then with 0.1 ng/ml IFN gamma for 24 h. e ChIP of Tri-methyl-histone H3 (H3K27me3), EZH2 & acetyl-histone4 (H4ac) was performed in BMDMs treated with 20 ng/ml LIF for 72 h. Scheme shows the analysed CXCL9 promoter region. Representative data are presented as mean ± SD. f Representative images of IF of the indicated markers in human GBM organotypic slices (patients 1, 2, 3) incubated with 10 μg/ml anti-LIF for 3 days. Scale bar, 20 μm. (see Supplementary Fig. 8). Bottom, percentage of double positive cells relative to Iba1+ cells & percentage of CXCL9+ cells relative to the total number of cells. Data are mean of all patients ± SEM. Statistical analyses by Student’s t-test or Mann–Whitney T-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-3102024161360.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202416114760.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-31020241613617.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0010.jpg "<b>Biological Strategies Validation. </b>Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC and EA treatment on the expression of mBDNF and NT4 in neurons. Photomicrographs for mBDNF/NeuN or NT4/NeuN double-positive cells in the striatum and hippocampus (n = 5). The number of mBDNF/NeuN double-positive cells in the SVZ + striatum and hippocampus was significantly higher in the EA-treated MCAO group and the combined mBMSC + EA-treated MCAO group, compared to the number in the other groups. The number of NT4/NeuN double-positive cells in the hippocampus was significantly higher in the EA-treated MCAO group than in the vehicle-treated MCAO group. #p < 0.05 and ##p < 0.01 versus control group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus vehicle-treated MCAO group; &&p < 0.01 versus mBMSC-treated MCAO group. Scale bar = 100 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-018-20481-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-NB100-98682-img0007.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Human platelet lysate and recombinant mature BDNF. Blocking: 1% LFDM for 30 min at RT; primary antibody (1:1000) incubated at 4C overnight.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0006.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0001.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0003.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0005.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415371951.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415175223.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Antagonized TrkB could restrain the activation of astrocytes & microglia & supress the p38/JNK pathway to alleviate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. Western blots showed that the overexpression of a BDNF, b TrkB, cp-TrkB, d Iba1, e GFAP, fp-p38, gp-JNK, h TNF-alpha , & i IL-1 beta were downregulated in comparison to the CYP + DMSO group after ANA-12 treatment. All data were calculated as mean ± SEM (n = 5 per group). **p < 0.01, ***p < 0.001 vs. control group. ##p < 0.01, ###p < 0.001 vs. CYP + ANA-12 group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415291934.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further & promoted activation of astrocytes & microglia, & enhanced the p38/JNK pathway to aggravate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. a BDNF treated every other day after CYP injection could further lower the mechanical withdrawal threshold & suppress the retrieval of mechanical threshold when compared with the CYP + PBS group. After the exogenous BDNF injection, Western blots showing the expression of b BDNF, c TrkB, dp-TrkB, e Iba1, f GFAP, gp-p38, hp-JNK, i TNF-alpha , & j IL-1 beta were all further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284921.jpg)
![Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC & EA treatment on the expression of trophic factors. (A) Photomicrographs & (B‒D) histograms for mBDNF, NT4, & VEGF expression (n = 4–5). mBDNF expression was markedly increased by treatment with mBMSC and/or EA compared to vehicle treatment. mBDNF expression levels were higher in the EA-treated MCAO group than in the mBMSC-treated MCAO group. NT4 expression in the SVZ & hippocampus was significantly higher in the combined mBMSC & EA treatment group than in the other groups. VEGF expression in the hippocampus was markedly higher in the mBMSC treatment group than in the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, & ###p < 0.001 versus control group; *p < 0.05, **p < 0.01, & ***p < 0.001 versus vehicle-treated MCAO group; &p < 0.05, &&p < 0.01, & &&&p < 0.001 versus mBMSC-treated MCAO group; Scale bar = 1 mm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29391466), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284912.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - The expression of BDNF-TrkB signaling in the SDH of CYP-induced cystitis. a Changes of the mechanical threshold in CYP-induced cystitis model. Compared to that in the control group, the mechanical threshold of the cystitis group decreased significantly after the CYP injection & remained low until day 17, & the minimum threshold value was reached on day 12. The expression of b BDNF, c TrkB, & dp-TrkB were evaluated by western blots. Compared to the control group, they were upregulated on days 8, 12, & 17. e Immunofluorescence double staining assay of BDNF & p-TrkB in the SDH. BDNF & p-TrkB (red), NeuN, GFAP, & OX-42( green), co-localization (yellow). BDNF was mainly colocalized in neurons which mainly located in Laminate II to IV. & TrkB receptors expressed in neurons, microglia, & astrocytes. The white dotted lines in picture “BDNF/NeuN” showed the laminate of the SDH according to Rexed & Steiner. Scale bar = 100 μm. All data were calculated as mean ± SEM (n = 5 per group). *p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284910.jpg)
![Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Analysis using Azide/BSA FREE version of NB600-587. Membrane blocked in 1% BSA-TBS-T 30 min RT, 1:1000 dilution in 1% BSA-TBS-T 4C.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Western-Blot-NB600-587-img0012.jpg "Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Analysis using Azide/BSA FREE version of NB600-587. Membrane blocked in 1% BSA-TBS-T 30 min RT, 1:1000 dilution in 1% BSA-TBS-T 4C.")
![Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Expression of TNF-alpha, IL-1beta and NF-kappaB in the brains of MCAO rats. Western blot confirmed that protein levels of TNF-alpha increased as early as 4 h after reperfusion, further increased at 24 h, peaked at 72 h and decreased at 7 days, respectively (*P<0.001, compared with the controls; #P<0.001 compared with the previous time point). Five rats in each group were used for western blot (n=5), sham, sham-operated control rats Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2014586), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Western-Blot-NB600-587-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: TNF-alpha Antibody - Azide Free [NB600-587] - LMP2 knockdown by shRNA reduced the expression of TNF-alpha and IL-1beta after MCAO. Immunofluorescence labeling revealed that both TNF-alpha and IL-1beta immunoreactivity was significantly upregulated in the ipsilateral ischemic hemisphere compared with sham-operated animals. In contrast, LMP2 knockdown by shRNA significantly reduced the expression of TNF-alpha and IL-1beta. Five rats in each group were used for immunofluorescent assays (n=5). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2014586), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Immunocytochemistry-Immunofluorescence-NB600-587-img0015.jpg)
![Immunohistochemistry: TNF-alpha Antibody - Azide Free [NB600-587] - Staining of formalin/PFA-fixed paraffin-embedded sections of human artery tissue sections. Sections were fixed in formaldehyde and subjected to heat mediated antigen retrieval in citrate buffer (pH 6.0). Slides were blocked for ten minutes with 1.5% serum. Primary antibody was diluted 1:100 and incubated with samples for 24 hours at 4C. HRP-conjugated goat anti-rabbit antibody was used as the secondary antibody.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Immunohistochemistry-NB600-587-img0008.jpg)
![Western Blot: TNF-alpha Antibody - Azide Free [NB600-587] - Expression of TNF-alpha, IL-1beta and NF-kappaB in the brains of MCAO rats. Western blot confirmed that protein levels of TNF-alpha increased as early as 4 h after reperfusion, further increased at 24 h, peaked at 72 h and decreased at 7 days, respectively (*P<0.001, compared with the controls; #P<0.001 compared with the previous time point). Five rats in each group were used for western blot (n=5), sham, sham-operated control rats Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2014586), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody---Azide-Free-Western-Blot-NB600-587-img0013.jpg)
![Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of lymph nodes by multiple staining.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Flow-Cytometry-NBP1-49045-img0014.jpg "Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of lymph nodes by multiple staining.")
![Immunohistochemistry-Paraffin: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - CD8 alpha expression in mouse spleen tissue using anti-CD8 alpha antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Immunohistochemistry-Paraffin-NBP1-49045-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of bone marrow tissue by single and multiple staining.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Immunocytochemistry-Immunofluorescence-NBP1-49045-img0006.jpg)
![Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Staining of peripheral blood leukocytes.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Flow-Cytometry-NBP1-49045-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of immersion fixed splenocytes. Primary antibody was used at a dilution of 10 ug/mL and incubated for 3 hours at room temperature.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Immunocytochemistry-Immunofluorescence-NBP1-49045-img0011.jpg)
![Immunohistochemistry: CD8 Antibody (53-6.7) [NBP1-49045] - Histopathological analysis of spinal cord in EAE mice. Representative spinal cord sections from wild-type (WT), Asic1-/- , and Asic2-/- mice at 45 days after immunization. Sections of the spinal cord anterior horn were stained with hematoxylin and eosin (E&H) to assess inflammation and immunostained for MCHII, CD4+, CD8+ infiltrating cells. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/abs/10.1111/ejn.14302), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Immunohistochemistry-NBP1-49045-img0016.jpg)
![Flow Cytometry: CD8 Antibody (53-6.7) - BSA Free [NBP1-49045] - Analysis of isolated mouse splenic CD8+ T cells using CD8 antibody (53-6.7) [Allophycocyanin] (NBP1-49045APC). Image from verified customer review.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-BSA-Free-Flow-Cytometry-NBP1-49045-img0017.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of mosue spleen sections. CD8+ lymphocytes are marked by brown labeling of the cell surface.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Immunohistochemistry-Frozen-NBP1-49045-img0008.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody (53-6.7) [NBP1-49045] - Analysis of CD8+ T cells in allogeneic skin grafted onto a mouse.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Immunohistochemistry-Frozen-NBP1-49045-img0015.jpg)
![Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - Analysis of fixed murine splenocytes by multiple staining.](http://images.novusbio.com/fullsize/CD8-Antibody-53-6-7-Flow-Cytometry-NBP1-49045-img0009.jpg)
![Immunohistochemistry-Paraffin: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - CD8 alpha expression in human spleen tissue using anti-CD8 alpha antibody.](http://images.novusbio.com/fullsize/antibody/nbp1-49045_rat-monoclonal-cd8-antibody-53-6-7-immunohistochemistry-paraffin-2210202583119.jpg)